Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002388 · ClinicalTrials.gov registry record · Phase 1
A Study of 1592U89 in HIV-Infected Patients
A Phase 1 study, sponsored by Glaxo Wellcome.
- Completed
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
NCT00002388: Completed Phase 1 study, sponsored by Glaxo Wellcome.
NCT00002388 is a Phase 1 study that has completed, run by Glaxo Wellcome. The registered enrollment target is 48 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (20% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002388, a Phase 1 study, has completed, sponsored by Glaxo Wellcome.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
Study Summary
The purpose of this study is to see if it is safe to give 1592U89 to HIV-infected patients. This study also examines the effect 1592U89 has on plasma viral load (the level of HIV in the blood).
Interventions
- DRUG Abacavir sulfate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Phase | Phase 1 |
What the finished NCT00002388 record still lists
NCT00002388 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 48 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (20% lower).
The record links to 0 conditions, and to 1 intervention - of which Abacavir sulfate is the first listed.
NCT00002388 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00002388 about?
NCT00002388 is a clinical study titled "A Study of 1592U89 in HIV-Infected Patients". The purpose of this study is to see if it is safe to give 1592U89 to HIV-infected patients. This study also examines the effect 1592U89 has on plasma viral load (the level of HIV in the blood).
What is the current status of trial NCT00002388?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants.
What interventions are being tested in trial NCT00002388?
The interventions under investigation include: Abacavir sulfate (DRUG).
Who is sponsoring clinical trial NCT00002388?
This trial is sponsored by Glaxo Wellcome, which has 65 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00002388's enrollment target sits among peer trials
48 1025th of 2000 higher than 948 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01765777 · 48 participants · NA
Efficacy of Osteopathic Manipulative Medicine (OMM) and Phototherapy for Patients With Chronic Lower Back Pain
- NCT03073343 · 48 participants · NA
A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine
- NCT03431064 · 48 participants
Lung Recruitment Maneuver as a Potential Predictor of Fluid Responsiveness in Mechanically Ventilated Pediatric Patients
- NCT03514602 · 48 participants · NA
Maternal Smoking Cessation and Pediatric Obesity Prevention